The road map to oral bioavailability: an industrial perspective.
about
Discovery of Novel Imidazo[4,5- b ]pyridines as Potent and Selective Inhibitors of Phosphodiesterase 10A (PDE10A)The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data.How to report and discuss ADME data in medicinal chemistry publications: in vitro data or in vivo extrapolations?Innovative oral spray-dried Idebenone systems to improve patient compliance.Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo data.Discovery of a Novel Class of Imidazo[1,2-a]Pyridines with Potent PDGFR Activity and Oral Bioavailability.New p32/gC1qR Ligands for Targeted Tumor Drug Delivery.Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse.Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers.Lead identification and structure-activity relationships of heteroarylpyrazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.Application of Caco-2 cell line in herb-drug interaction studies: current approaches and challengesImpact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans.Targeting tumor hypoxia with 2-nitroimidazole-indocyanine green dye conjugates.Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety.Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis.Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination.Inorganic matrices: an answer to low drug solubility problem.Fabrication, modeling and characterization of multi-crosslinked methacrylate copolymeric nanoparticles for oral drug delivery.Discovery and Optimization of Tetramethylpiperidinyl Benzamides as Inhibitors of EZH2Design and evaluation of Lumefantrine - Oleic acid self nanoemulsifying ionic complex for enhanced dissolution.Flavonoid from Carica papaya inhibits NS2B-NS3 protease and prevents Dengue 2 viral assembly.Quantifying and Communicating Uncertainty in Preclinical Human Dose-Prediction.Mass Spectrometry Imaging proves differential absorption profiles of well-characterised permeability markers along the crypt-villus axisDiscovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5).Effect of chitosan glutamate, carbomer 974P, and EDTA on the in vitro Caco-2 permeability and oral pharmacokinetic profile of acyclovir in rats.Rat poorly predicts the combined non-absorbed and presystemically metabolized fractions in the human.Blockade of Asparagine Endopeptidase Inhibits Cancer Metastasis.Solubility and dissolution enhancement strategies: current understanding and recent trends.Investigation of the prerequisites for the optimization of specific plasma protein binding as a strategy for the reduction of first-pass hepatic metabolism.
P2860
Q27684392-FD9A640E-1A85-4842-A9FF-3AA35279A8C9Q30670381-D0D854BE-1BAD-438A-9CAA-E0A4F5B8F316Q30920065-642999EA-670A-428E-AD5E-FC8396C67ABCQ31021104-E231FFAF-A428-4258-92A8-C2F3F45AEB05Q33496817-829D636B-CD70-409B-9081-1AD9D150F93DQ33636171-8C3E6087-2D13-480B-8884-31A65948F1F3Q33694228-9E5B3B93-AC1F-4682-9522-1AB7A6937B69Q34749181-7D5D9891-AA54-450D-B173-F845D3A5AB6BQ34757166-AAC26597-B644-4B41-AFD5-B1C2D19B140BQ35090956-4A399DEB-D33F-4643-8023-B0988B8369E3Q35164876-5452DE72-7D05-405B-8BBF-3A32AB912127Q36909306-D7FB95C5-E904-4C68-B3D7-3755D55DA0FAQ36923843-FF4C63EF-A45D-4DA2-9A0C-A5488044AD23Q36960535-9E1F2821-9C95-4C64-97B1-B3821FCE6182Q37069968-F48FA16C-88D3-4464-874A-232241E095CDQ37600381-46ED8B37-AD49-4F05-8AF1-9311A9B65330Q38051672-29D22EC7-65D7-4A9A-B31B-EF6EBE11B1F1Q38661732-F90BBDF5-BEA9-4553-8D9E-2FA0DF142C83Q39785596-3E1911E3-1434-4390-9FF8-6BE36A8FA195Q40098763-A9BC7AC7-F707-4E77-BF71-2490038A1FC7Q40226025-D46014C1-350D-4AAB-8D96-AEADD9FB1FBFQ40606599-D2002715-FB36-4388-8C58-E91B3A68111EQ41124799-7C6987AB-50AE-40D9-8662-BECD21295C89Q41844464-7FB01E0C-852D-438A-A36E-43FB4D984E4AQ46084651-464F8C34-2989-4576-94B5-2D7D79DE552BQ46977325-67CC3289-71F0-419C-85E1-95F72047D2C8Q48217437-2279C2EF-862B-469A-97BF-9AFEC2D8064FQ51020710-DFEE8879-D46F-44C2-A8BF-70AC2F498070Q51038149-C61E7349-D371-4312-8987-A2FBA6B71872
P2860
The road map to oral bioavailability: an industrial perspective.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The road map to oral bioavailability: an industrial perspective.
@ast
The road map to oral bioavailability: an industrial perspective.
@en
type
label
The road map to oral bioavailability: an industrial perspective.
@ast
The road map to oral bioavailability: an industrial perspective.
@en
prefLabel
The road map to oral bioavailability: an industrial perspective.
@ast
The road map to oral bioavailability: an industrial perspective.
@en
P2093
P2860
P356
P1476
The road map to oral bioavailability: an industrial perspective.
@en
P2093
Ayman El-Kattan
Chad L Stoner
Linda Hitchingham
Maryanne Naath
Narayanan Surendran
Philip Zocharski
Shobha Bhattachar
V Hayden Thomas
P2860
P304
P356
10.1517/17425255.2.4.591
P407
P577
2006-08-01T00:00:00Z